Voncento

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
13-05-2022
Produktens egenskaper Produktens egenskaper (SPC)
13-05-2022

Aktiva substanser:

Human coagulation factor VIII, human von willebrand factor

Tillgänglig från:

CSL Behring GmbH

ATC-kod:

B02BD06

INN (International namn):

human coagulation factor VIII / human von willebrand factor

Terapeutisk grupp:

Blood coagulation factors, von Willebrand factor and coagulation factor VIII in combination, Antihemorrhagics

Terapiområde:

Hemophilia A; von Willebrand Diseases

Terapeutiska indikationer:

Von Willebrand disease (VWD)Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.Haemophilia A (congenital factor-VIII deficiency)Prophylaxis and treatment of bleeding in patients with haemophilia A.

Produktsammanfattning:

Revision: 15

Bemyndigande status:

Authorised

Tillstånd datum:

2013-08-12

Bipacksedel

                                41
B. PACKAGE LEAFLET
42
PACKAGE LEAFLET: INFORMATION FOR THE USER
VONCENTO 250 IU FVIII / 600 IU VWF (5 ML SOLVENT) POWDER AND SOLVENT
FOR SOLUTION FOR
INJECTION/INFUSION
VONCENTO 500 IU FVIII / 1200 IU VWF(10 ML SOLVENT) POWDER AND SOLVENT
FOR SOLUTION FOR
INJECTION/INFUSION
VONCENTO 500 IU FVIII / 1200 IU VWF (5 ML SOLVENT) POWDER AND SOLVENT
FOR SOLUTION FOR
INJECTION/INFUSION
VONCENTO 1000 IU FVIII / 2400 IU VWF (10 ML SOLVENT) POWDER AND
SOLVENT FOR SOLUTION FOR
INJECTION/INFUSION
human coagulation factor VIII,
human von Willebrand factor
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have further questions, ask your doctor, your nurse or your
pharmacist.

This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.

If you get any side effects talk to your doctor, nurse or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Voncento is and what it is used for
2.
What you need to know before you use Voncento
3.
How to use Voncento
4.
Possible side effects
5.
How to store Voncento
6.
Contents of the pack and other information
1.
WHAT VONCENTO IS AND WHAT IT IS USED FOR
The product is made from human plasma (the liquid part of the blood)
and contains the active
substances called human coagulation factor VIII (FVIII) and human von
Willebrand factor (VWF).
Voncento is used for all age groups to prevent or to halt bleeding
caused by the lack of VWF in von
Willebrand disease (VWD) and the lack of FVIII in haemophilia A.
Voncento is only used when
treatment with another medicine, desmopressin, is not effective alone
or cannot be given.
VWF and FVIII are involved in blood clotting. Lack of either factor
means that blood does not clot as
quickly as it should so there is an increased tendency to bleed. The
replacemen
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent
for solution for
injection/infusion
Voncento 500 IU FVIII /1200 IU VWF (10 ml solvent) powder and solvent
for solution for
injection/infusion
Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent
for solution for
injection/infusion
Voncento 1000 IU FVIII / 2400 IU VWF (10 ml solvent) powder and
solvent for solution for
injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Voncento 250 IU FVIII / 600 IU VWF powder and solvent for solution for
injection/infusion
One vial of powder contains nominally:
-
250 IU* human coagulation factor VIII** (FVIII).
-
600 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 5 ml water for injections provided, the
solution contains 50 IU/ml of
FVIII and 120 IU/ml of VWF.
Voncento 500 IU FVIII / 1200 IU VWF powder and solvent for solution
for injection/infusion
One vial of powder contains nominally:
-
500 IU* human coagulation factor VIII** (FVIII).
-
1200 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 10 ml water for injections provided, the
solution contains 50 IU/ml of
FVIII and 120 IU/ml of VWF.
Voncento 500 IU FVIII / 1200 IU VWF powder and solvent for solution
for injection/infusion
One vial of powder contains nominally:
-
500 IU* human coagulation factor VIII** (FVIII).
-
1200 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 5 ml water for injections provided, the
solution contains 100 IU/ml of
FVIII and 240 IU/ml of VWF.
Voncento 1000 IU FVIII / 2400 IU VWF powder and solvent for solution
for injection/infusion
One vial of powder contains nominally:
-
1000 IU* human coagulation factor VIII** (FVIII).
-
2400 IU*** human von Willebrand factor** (VWF).
After reconstitution with the 10 ml water for injections provided, the
solution contains 100 IU/ml of
FVIII and 240 IU/ml of VWF.
_________________________________________
* The FVIII poten
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 13-05-2022
Produktens egenskaper Produktens egenskaper bulgariska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 16-01-2018
Bipacksedel Bipacksedel spanska 13-05-2022
Produktens egenskaper Produktens egenskaper spanska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 16-01-2018
Bipacksedel Bipacksedel tjeckiska 13-05-2022
Produktens egenskaper Produktens egenskaper tjeckiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 16-01-2018
Bipacksedel Bipacksedel danska 13-05-2022
Produktens egenskaper Produktens egenskaper danska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 16-01-2018
Bipacksedel Bipacksedel tyska 13-05-2022
Produktens egenskaper Produktens egenskaper tyska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 16-01-2018
Bipacksedel Bipacksedel estniska 13-05-2022
Produktens egenskaper Produktens egenskaper estniska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 16-01-2018
Bipacksedel Bipacksedel grekiska 13-05-2022
Produktens egenskaper Produktens egenskaper grekiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 16-01-2018
Bipacksedel Bipacksedel franska 13-05-2022
Produktens egenskaper Produktens egenskaper franska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 16-01-2018
Bipacksedel Bipacksedel italienska 13-05-2022
Produktens egenskaper Produktens egenskaper italienska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 16-01-2018
Bipacksedel Bipacksedel lettiska 13-05-2022
Produktens egenskaper Produktens egenskaper lettiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 16-01-2018
Bipacksedel Bipacksedel litauiska 13-05-2022
Produktens egenskaper Produktens egenskaper litauiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 16-01-2018
Bipacksedel Bipacksedel ungerska 13-05-2022
Produktens egenskaper Produktens egenskaper ungerska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 16-01-2018
Bipacksedel Bipacksedel maltesiska 13-05-2022
Produktens egenskaper Produktens egenskaper maltesiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 16-01-2018
Bipacksedel Bipacksedel nederländska 13-05-2022
Produktens egenskaper Produktens egenskaper nederländska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 16-01-2018
Bipacksedel Bipacksedel polska 13-05-2022
Produktens egenskaper Produktens egenskaper polska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 16-01-2018
Bipacksedel Bipacksedel portugisiska 13-05-2022
Produktens egenskaper Produktens egenskaper portugisiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 16-01-2018
Bipacksedel Bipacksedel rumänska 13-05-2022
Produktens egenskaper Produktens egenskaper rumänska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 16-01-2018
Bipacksedel Bipacksedel slovakiska 13-05-2022
Produktens egenskaper Produktens egenskaper slovakiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 16-01-2018
Bipacksedel Bipacksedel slovenska 13-05-2022
Produktens egenskaper Produktens egenskaper slovenska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 16-01-2018
Bipacksedel Bipacksedel finska 13-05-2022
Produktens egenskaper Produktens egenskaper finska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 16-01-2018
Bipacksedel Bipacksedel svenska 13-05-2022
Produktens egenskaper Produktens egenskaper svenska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 16-01-2018
Bipacksedel Bipacksedel norska 13-05-2022
Produktens egenskaper Produktens egenskaper norska 13-05-2022
Bipacksedel Bipacksedel isländska 13-05-2022
Produktens egenskaper Produktens egenskaper isländska 13-05-2022
Bipacksedel Bipacksedel kroatiska 13-05-2022
Produktens egenskaper Produktens egenskaper kroatiska 13-05-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 16-01-2018

Sök varningar relaterade till denna produkt

Visa dokumenthistorik